.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Deloitte
Chubb
Queensland Health
Daiichi Sankyo
Novartis
Chinese Patent Office
Healthtrust
Teva
Cerilliant

Generated: July 28, 2017

DrugPatentWatch Database Preview

ALSUMA Drug Profile

« Back to Dashboard

Which patents cover Alsuma, and when can generic versions of Alsuma launch?

Alsuma is a drug marketed by Meridian Medcl and is included in one NDA. There is one patent protecting this drug.

This drug has four patent family members in four countries.

The generic ingredient in ALSUMA is sumatriptan succinate. There are twenty-three drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

Summary for Tradename: ALSUMA

Patents:1
Applicants:1
NDAs:1
Bulk Api Vendors: see list67
Patent Applications: see list1,107
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ALSUMA at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Meridian Medcl
ALSUMA
sumatriptan succinate
INJECTABLE;SUBCUTANEOUS022377-001Jun 29, 2010DISCNNoNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ALSUMA

Country Document Number Estimated Expiration
Taiwan200838574► Subscribe
Canada2666860► Subscribe
World Intellectual Property Organization (WIPO)2008048750► Subscribe
European Patent Office2073866► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Moodys
QuintilesIMS
AstraZeneca
Fuji
Julphar
Chubb
Cipla
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot